Procter & Gamble Health Limited Stock Price Today (NSE: PGHL)
Fundamental Score
Procter & Gamble Health Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Procter & Gamble Health Limited share price today is ₹5460.00, up +0.96% on NSE/BSE as of 16 September 2026. Procter & Gamble Health Limited (PGHL) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹9.06K (Cr). The 52-week high for PGHL share price is ₹6975.00 and the 52-week low is ₹4707.00. At a P/E ratio of 25.40x, PGHL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 61.59% and a debt-to-equity ratio of 0.00.
Procter & Gamble Health Limited Share Price Chart — NSE/BSE Historical Performance
Procter & Gamble Health Limited share price chart: -8.23% return over the past month. 52-week high ₹6975.00, 52-week low ₹4707.00.
Procter & Gamble Health Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹5365.00 | ₹5568.00 | ₹5365.00 | ₹5460.00 | 13.56K (Cr) | |
| ₹5405.00 | ₹5459.50 | ₹5363.50 | ₹5408.00 | 10.41K (Cr) | |
| ₹5430.00 | ₹5470.50 | ₹5302.50 | ₹5411.50 | 7.71K (Cr) | |
| ₹5442.00 | ₹5505.00 | ₹5405.00 | ₹5425.50 | 15.87K (Cr) | |
| ₹5598.00 | ₹5598.00 | ₹5451.00 | ₹5475.00 | 8.07K (Cr) | |
| ₹5675.00 | ₹5675.00 | ₹5585.50 | ₹5603.00 | 4.34K (Cr) | |
| ₹5699.50 | ₹5706.50 | ₹5650.00 | ₹5667.00 | 4.98K (Cr) | |
| ₹5757.50 | ₹5780.00 | ₹5650.00 | ₹5660.00 | 7.25K (Cr) | |
| ₹5680.00 | ₹5773.00 | ₹5646.00 | ₹5757.50 | 7.53K (Cr) | |
| ₹5750.00 | ₹5759.50 | ₹5662.50 | ₹5669.50 | 4.58K (Cr) |
Procter & Gamble Health Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹5741.00 | ₹5825.00 | ₹5302.50 | ₹5460.00 | -4.89% | |
| ₹6604.50 | ₹6699.50 | ₹5640.00 | ₹5768.00 | -12.67% | |
| ₹6396.50 | ₹6975.00 | ₹6202.50 | ₹6604.50 | +3.25% | |
| ₹6056.00 | ₹6399.00 | ₹5921.50 | ₹6326.50 | +4.47% | |
| ₹5235.50 | ₹6700.00 | ₹5067.00 | ₹6056.00 | +15.67% | |
| ₹4829.00 | ₹5260.00 | ₹4707.00 | ₹5216.90 | +8.03% | |
| ₹4949.00 | ₹5011.00 | ₹4725.00 | ₹4798.80 | -3.03% | |
| ₹5300.50 | ₹5480.00 | ₹4862.00 | ₹4900.50 | -7.55% | |
| ₹5679.00 | ₹5912.00 | ₹5290.00 | ₹5303.00 | -6.62% | |
| ₹5723.00 | ₹5870.00 | ₹5541.50 | ₹5703.00 | -0.35% | |
| ₹6174.00 | ₹6180.00 | ₹5698.50 | ₹5722.50 | -7.31% | |
| ₹6306.50 | ₹6409.00 | ₹6000.00 | ₹6166.50 | -2.22% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Procter & Gamble Health Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Procter & Gamble Health Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of PGHL across key market metrics for learning purposes.
Positive Indicators
11 factors identified
Strong Return on Equity (61.59%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (77.30%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (27.43%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 25.40 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (45.29%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (818.93x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 2.39)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹1017.62 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (51.82%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
High Price-to-Book Ratio (16.84x)
Observation: Trading at significant premium to book value.
Analysis: High P/B ratios may indicate overvaluation relative to asset base.
Limited Growth History (0.76% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (4.98% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (4.98% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Procter & Gamble Health Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Procter & Gamble Health Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
63.9/100 | ₹5460.00₹5460 | ₹9063.60₹9063.60 | 25.40Average 25.4 Average | 61.59%Excellent 61.59% Excellent | 77.30%Excellent 77.30% Excellent | 0.00Excellent 0.0 Excellent | 4.98%Average 4.98% Average | 0.76%Average 0.76% Average | 2.26% | |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Procter & Gamble Health Limited PE Ratio History
Historical price-to-earnings ratio for PGHL — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹121.00 | ₹5238.05 | 43.3x |
| FY 2023 | ₹138.00 | ₹4947.75 | 35.9x |
| FY 2022 | ₹115.98 | ₹3953.00 | 34.1x |
| FY 2021 | ₹107.00 | ₹5338.40 | 49.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Procter & Gamble Health Limited Dividend History
Annual cash dividends paid by PGHL — dividend yield 2.26%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2024 | ₹414.99 Cr |
| FY 2023 | ₹93.79 Cr |
| FY 2022 | ₹283.85 Cr |
| FY 2021 | ₹381.78 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Procter & Gamble Health Limited Quarterly Performance
Latest quarterly metrics for PGHL — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.37%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
45.29%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
0.76%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
4.98%
Compounded annual net profit growth over 5 years
Procter & Gamble Health Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for PGHL — calculated from daily price history
Selling pressure is heavy — potential reversal zone.
Technical indicators are for educational purposes only. Not investment advice.
Procter & Gamble Health Limited Financial Statements
Annual income statement, balance sheet and cash flow for Procter & Gamble Health Limited (PGHL) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Procter & Gamble Health Limited
About PGHL (Procter & Gamble Health Limited)
Procter & Gamble Health Ltd is a dynamic player in the pharmaceutical sector, deeply rooted in both the Indian and global markets. The company is dedicated to enhancing consumer we...ll-being through a diverse portfolio of over-the-counter medicines and a comprehensive range of vitamins, minerals, and supplements. PGHL's commitment to quality and innovation is evident in its focus on providing accessible healthcare solutions, aimed at improving the everyday lives of individuals and families. With a strong emphasis on research and development, PGHL continuously strives to formulate effective and reliable products that address a variety of health needs, strengthening its position as a trusted name in the consumer healthcare landscape. The company's recognized and established brand portfolio, which includes names like Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas, reflects its longstanding presence and trusted reputation among consumers. These brands encompass a wide spectrum of health solutions, targeting various needs from multivitamin supplementation to specialized treatments. Procter & Gamble Health Ltd leverages these established brands to reach diverse consumer segments, reinforcing its commitment to providing accessible healthcare solutions. This strategic approach allows the company to maintain a competitive edge and to foster lasting relationships with customers who depend on the quality and reliability of PGHL products. Originally established as Merck Limited in 1967, the company underwent a transformative rebranding to Procter & Gamble Health Limited in May 2019, marking a significant milestone in its journey. This transition not only reflects the company's integration into the global Procter & Gamble network but also signifies its renewed focus on consumer healthcare. Procter & Gamble Health Ltd continues to build upon its legacy of scientific expertise and market understanding, while leveraging the resources and global reach of its parent company. With a history of delivering innovative healthcare solutions, PGHL is poised to continue its mission of improving health and well-being for consumers across India and beyond.
Company Details
Key Leadership
PGHL Share Price: Frequently Asked Questions
What is the current share price of Procter & Gamble Health Limited?
Procter & Gamble Health Limited (PGHL) trades at ₹5460.00 on NSE and BSE. Market cap ₹9.06K (Cr). Educational data only.
What is the P/E ratio of Procter & Gamble Health Limited?
Procter & Gamble Health Limited has a P/E of 25.40x vs industry average 34.89x.
What is the Bull Run score for Procter & Gamble Health Limited?
Procter & Gamble Health Limited has a Bull Run score of 63.9/100 based on 25+ financial parameters.
Does Procter & Gamble Health Limited pay dividends?
Procter & Gamble Health Limited has a dividend yield of 2.26%. Past dividends don't guarantee future payments.
What is the ROE of Procter & Gamble Health Limited?
Procter & Gamble Health Limited has ROE of 61.59%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Procter & Gamble Health Limited?
Procter & Gamble Health Limited has debt-to-equity of 0.00.
Is Procter & Gamble Health Limited a good investment?
Bull Run gives Procter & Gamble Health Limited a score of 63.9/100. This is not investment advice — consult a SEBI-registered advisor.